Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters
Clostridium difficile infection (CDI) has been identified as the leading cause of nosocomial diarrhoea and pseudomembranous colitis associated with antibiotic therapy. Recent epidemiological changes as well as increases in the number of outbreaks of strains associated with increased virulence and higher mortality rates underscore the importance of identifying alternatives to antibiotics to manage this important disease. Animal studies have clearly demonstrated the roles that toxins A and B play in gut inflammation as well as diarrhoea; therefore it is not surprising that serum anti-toxin A and B IgG are associated with protection against recurrent CDI. In humans, strong humoral toxin-specific immune responses elicited by natural C. difficile infection is associated with recovery and lack of disease recurrence, whereas insufficient humoral responses are associated with recurrent CDI. The first generation of C. difficile vaccine that contained inactivated toxin A and B was found to be completely protective against death and diarrhoea in the hamster C. difficile challenge model. When tested in young healthy volunteers in Phase I clinical trials, this investigational vaccine was shown to be safe and immunogenic. Moreover, in a separate study this vaccine was able to prevent further relapses in three out of three patients who had previously suffered from chronic relapsing C. difficile-associated diarrhoea. Herein we examined the immunogenicity and protective activity of a next-generation Sanofi Pasteur two-component highly purified toxoid vaccine in a C. difficile hamster model. This model is widely recognized as a stringent and relevant choice for the evaluation of novel treatment strategies against C. difficile and was used in preclinical testing of the first-generation vaccine candidate. Intramuscular (i.m.) immunizations with increasing doses of this adjuvanted toxoid vaccine protected hamsters from mortality and disease symptoms in a dose-dependent manner. ELISA measurements of pre-challenge sera showed that the median anti-toxin A and anti-toxin B IgG titres in the group of surviving animals were significantly higher than the median values in the group of animals that did not survive challenge. Assessment of the neutralizing activity of these sera revealed a statistically significant difference between the levels of both toxin A and toxin B neutralizing titres in protected versus unprotected animals as the median anti-toxin A and anti-toxin B neutralizing titres from surviving animals were higher than the median values from animals that succumbed to challenge. Statistically significant correlations between the toxin-specific binding titres and toxin neutralizing titres were seen for both toxin A and toxin B responses. The role of circulating anti-toxin antibodies in immunity against disease was evaluated by passive transfer of immune sera against C. difficile toxoids to naïve hamsters. Passively immunized animals were protected against morbidity and mortality associated with C. difficile challenge. Taken together, these results indicate the ability of i.m. immunization with inactivated toxins A and B to induce robust dose-dependent anti-toxin A and anti-toxin B IgG responses, the principal role of circulating anti-toxin antibody in immunity against disease and that antibody toxin binding and neutralization titres can serve as correlates of protection in the hamster challenge model of C. difficile.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BabcockG. J.,
BroeringT. J.,
HernandezH. J.,
MandellR. B.,
DonahueK.,
BoatrightN.,
StackA. M.,
LowyI.,
GrazianoR.other authors2006; Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74:6339–6347 [View Article][PubMed]
CohenS. H.,
GerdingD. N.,
JohnsonS.,
KellyC. P.,
LooV. G.,
McDonaldL. C.,
PepinJ.,
WilcoxM. H.Society for Healthcare Epidemiology of AmericaInfectious Diseases Society of America2010; Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31:431–455 [View Article][PubMed]
FangA.,
GersonD. F.,
DemainA. L.2009; Production of Clostridium difficile toxin in a medium totally free of both animal and dairy proteins or digests. PNAS 106:13225–13229[PubMed][CrossRef]
FernieD. S.,
ThomsonR. O.,
BattyI.,
WalkerP. D.1983; Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand 53:325–332[PubMed]
GiannascaP. J.,
WarnyM.2004; Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 22:848–856 [View Article][PubMed]
JinK.,
WangS.,
ZhangC.,
XiaoY.,
LuS.,
HuangZ.2013; Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B. Hum Vaccin Immunother 9:63–73 [View Article][PubMed]
JohnsonA. P.,
WilcoxM. H.2012; Fidaxomicin: a new option for the treatment of Clostridium difficile infection. J Antimicrob Chemother 67:2788–2792 [View Article][PubMed]
KimP. H.,
IaconisJ. P.,
RolfeR. D.1987; Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 55:2984–2992[PubMed]
KinkJ. A.,
WilliamsJ. A.1998; Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66:2018–2025[PubMed]
KuijperE. J.,
CoignardB.,
TüllP.ESCMID Study Group for Clostridium difficile EU Member StatesEuropean Centre for Disease Prevention and Control2006; Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12:Suppl 62–18 [View Article][PubMed]
KyneL.,
WarnyM.,
QamarA.,
KellyC. P.2000; Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342:390–397 [View Article][PubMed]
KyneL.,
WarnyM.,
QamarA.,
KellyC. P.2001; Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189–193 [View Article][PubMed]
LibbyJ. M.,
JortnerB. S.,
WilkinsT. D.1982; Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun 36:822–829[PubMed]
LouieT. J.,
MillerM. A.,
MullaneK. M.,
WeissK.,
LentnekA.,
GolanY.,
GorbachS.,
SearsP.,
ShueY. K.OPT-80-003 Clinical Study Group2011; Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422–431 [View Article][PubMed]
LowyI.,
MolrineD. C.,
LeavB. A.,
BlairB. M.,
BaxterR.,
GerdingD. N.,
NicholG.,
ThomasW. D.Jr,
LeneyM.other authors2010; Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197–205 [View Article][PubMed]
LyerlyD. M.,
PhelpsC. J.,
TothJ.,
WilkinsT. D.1986; Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun 54:70–76[PubMed]
McFarlandL. V.,
ElmerG. W.,
SurawiczC. M.2002; Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:1769–1775 [View Article][PubMed]
MillerM.,
GravelD.,
MulveyM.,
TaylorG.,
BoydD.,
SimorA.,
GardamM.,
McGeerA.,
HutchinsonJ.other authors2010; Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 50:194–201 [View Article][PubMed]
O’BrienJ. A.,
LahueB. J.,
CaroJ. J.,
DavidsonD. M.2007; The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 28:1219–1227 [View Article][PubMed]
PepinJ.2008; Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic?. Clin Infect Dis 46:1493–1498 [View Article][PubMed]
PermpoonpattanaP.,
HongH. A.,
PhetcharaburaninJ.,
HuangJ. M.,
CookJ.,
FairweatherN. F.,
CuttingS. M.2011; Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 79:2295–2302 [View Article][PubMed]
SteeleJ.,
MukherjeeJ.,
ParryN.,
TziporiS.2013; Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 207:323–330 [View Article][PubMed]
TianJ. H.,
FuhrmannS. R.,
Kluepfel-StahlS.,
CarmanR. J.,
EllingsworthL.,
FlyerD. C.2012; A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30:4249–4258 [View Article][PubMed]
TorresJ. F.,
LyerlyD. M.,
HillJ. E.,
MonathT. P.1995; Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 63:4619–4627[PubMed]
ViscidiR.,
LaughonB. E.,
YolkenR.,
Bo-LinnP.,
MoenchT.,
RyderR. W.,
BartlettJ. G.1983; Serum antibody response to toxins A and B of Clostridium difficile
. J Infect Dis 148:93–100 [View Article][PubMed]
Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters